CFHR1-2, Human, mAb JHD-7.10.1
The monoclonal antibody JHD-7.10.1 reacts with human complement factor H-related protein 1 and 2 (CFHR1/2). In humans the complement factor H protein family consists of complement factor H, the factor H-like protein 1 and five factor H-related proteins termed 1 to 5. All members of this group are expressed primarily in the liver and subsequently secreted into plasma. The secreted forms of these proteins are composed exclusively of repetitive protein domains termed short consensus repeats (SCR). The CFHR1 protein is composed of five SCR domains and circulates in plasma as two differentially glycosylated isoforms (37 kDa and 43 kDa). CFHR-2 is composed of four SCRs and is present in human plasma in a non-glycosylated form (24 kDa) and a glycosylated form of 29 kDa. So far the biological functions of both CFHR-1 and CFHR-2 proteins are poorly understood, however recent studies have shown that CFHR1 is a complement regulator that blocks C5 convertase activity as well as assembly and membrane insertion of the terminal components. Moreover, genetic variations in the CFHR1 gene are associated with several diseases such as atypical hemolytic uremic syndrome and age-related macular degeneration. Due to a high degree of amino acid sequence homology the monoclonal antibody is cross-reactive with both CFHR1 and 2. The antibody is suitable for immunoassay and Western blot applications.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA